XML 51 R25.htm IDEA: XBRL DOCUMENT
v3.20.1

Stock-Based Compensation | 3 Months Ended
--- | ---
Mar. 28, 2020
Share-based Payment Arrangement [Abstract] |
Share-Based Compensation | 18. Stock-Based Compensation Total stock-based compensation expense for the three months ended March 28, 2020 and March 30, 2019 was $11.3 million and $7.3 million, respectively. As of March 28, 2020, an aggregate of 10.2 million shares of common stock were reserved for future issuance under the Company’s equity plans, of which 1.9 million shares were available for future grant under the Masimo Corporation 2017 Equity Incentive Plan (2017 Equity Plan). Additional information related to the Company’s current equity incentive plans, stock-based award activity and valuation of stock-based awards is included below. Equity Incentive Plans 2017 Equity Incentive Plan On June 1, 2017, the Company’s stockholders ratified and approved the 2017 Equity Plan. The 2017 Equity Plan permits the grant of stock options, restricted stock, RSUs, stock appreciation rights, PSUs, performance shares, performance bonus awards and other stock or cash awards to employees, directors and consultants of the Company and employees and consultants of any parent or subsidiary of the Company. The aggregate number of shares that may be awarded under the 2017 Equity Plan is 5.0 million shares. The 2017 Equity Plan provides that at least 95% of the equity awards issued under the 2017 Equity Plan must vest over a period of not less than one year following the date of grant. The exercise price per share of each option granted under the 2017 Equity Plan may not be less than the fair market value of a share of the Company’s common stock on the date of grant, which is generally equal to the closing price of the Company’s common stock on the Nasdaq Global Select Market on the grant date. 2007 Stock Incentive Plan Effective June 1, 2017, upon the approval and ratification of the 2017 Equity Plan, the Company’s 2007 Stock Incentive Plan (2007 Equity Plan) terminated, provided that awards outstanding under the 2007 Equity Plan will continue to be governed by the terms of that plan. In addition, upon the effectiveness of the 2017 Equity Plan, an aggregate of 5.0 million shares of the Company’s common stock registered under prior registration statements for issuance pursuant to the 2007 Equity Plan were deregistered and concurrently registered under the 2017 Equity Plan. Stock-Based Award Activity Stock Options The number and weighted-average exercise price of options issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for exercise prices):
| Three Months Ended March 28, 2020
| Shares |  | Average Exercise Price
Options outstanding, beginning of period | 5,212 |  |  | $ | 54.23 |
Granted | 255 |  |  | 175.10 |
Canceled | (33 | ) |  | 112.65 |
Exercised | (384 | ) |  | 35.10 |
Options outstanding, end of period | 5,050 |  |  | $ | 61.42 |
Options exercisable, end of period | 3,245 |  |  | $ | 36.12 |
Total stock option expense for the three months ended March 28, 2020 and March 30, 2019 was $4.0 million and $3.5 million, respectively. As of March 28, 2020, the Company had $51.2 million of unrecognized compensation cost related to non-vested stock options that are expected to vest over a weighted average period of approximately 3.1 years. The weighted-average remaining contractual term of options outstanding with an exercise price less than the closing price of the Company’s common stock as of March 28, 2020 was 5.8 years. The weighted-average remaining contractual term of options exercisable, with an exercise price less than the closing price of the Company’s common stock as of March 28, 2020, was 4.5 years. RSUs The number of RSUs issued and outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted average grant date fair value amounts):
| Three Months Ended March 28, 2020
| Units |  | Weighted Average Grant Date Fair Value
RSUs outstanding, beginning of period | 2,797 |  |  | $ | 96.85 |
Granted | 72 |  |  | 178.71 |
Canceled | — |  |  | — |
Expired | — |  |  | — |
Vested | (17 | ) |  | 132.83 |
RSUs outstanding, end of period | 2,852 |  |  | $ | 98.72 |
Total RSU expense for the three months ended March 28, 2020 and March 30, 2019 was $1.0 million and $0.2 million, respectively. As of March 28, 2020, the Company had $22.4 million of unrecognized compensation cost related to non-vested RSU awards expected to be recognized and vest over a weighted-average period of approximately 4.2 years. PSUs The number of PSUs outstanding under all of the Company’s equity plans are as follows (in thousands, except for weighted average grant date fair value amounts):
| Three Months Ended March 28, 2020
| Units |  | Weighted Average Grant Date Fair Value
PSUs outstanding, beginning of period | 412 |  |  | $ | 102.22 |
Granted | 97 |  |  | 179.42 |
Canceled | — |  |  | — |
Expired | — |  |  | — |
Vested | (29 | ) |  | 90.69 |
PSUs outstanding, end of period | 480 |  |  | $ | 118.52 |
During the three months ended March 28, 2020, the Company awarded 97,000 PSUs that will vest three years from the award date, based on the achievement of certain 2022 performance criteria approved by the Board. If earned, the PSUs granted will vest upon achievement of the performance criteria after the year in which the performance achievement level has been determined. The number of shares that may be earned can range from 0% to 200% of the target amount; therefore, the maximum number of shares that can be issued under these awards is twice the original award of 97,000 PSUs or 194,000 shares. Based on management’s estimate of the number of units expected to vest, total PSU expense for the three months ended March 28, 2020 and March 30, 2019 was $6.3 million and $3.6 million, respectively. As of March 28, 2020, the Company had $62.4 million of unrecognized compensation cost related to non-vested PSU awards expected to be recognized and vest over a weighted-average period of approximately 1.6 years. Valuation of Stock-Based Award Activity The Black-Scholes option pricing model is used to estimate the fair value of options granted under the Company’s stock-based compensation plans. The range of assumptions used and the resulting weighted-average fair value of options granted at the date of grant were as follows:
| Three Months Ended
| March 28, 2020 |  | March 30, 2019
Risk-free interest rate | 0.4% to 1.7% |  | 2.2% to 2.6%
Expected term (in years) | 5.1 |  | 5.6
Estimated volatility | 26.9% to 27.2% |  | 29.3% to 30.0%
Expected dividends | 0% |  | 0%
Weighted-average fair value of options granted | $45.01 |  | $41.01
The aggregate intrinsic value of options is calculated as the positive difference, if any, between the market value of the Company’s common stock on the date of exercise or the respective period end, as appropriate, and the exercise price of the options. The aggregate intrinsic value of options outstanding with an exercise price less than the closing price of the Company’s common stock as of March 28, 2020 was $594.0 million. The aggregate intrinsic value of options exercisable with an exercise price less than the closing price of the Company’s common stock as of March 28, 2020 was $463.7 million. The aggregate intrinsic value of options exercised during the three months ended March 28, 2020 was $54.6 million. The fair value of each RSU and PSU award is determined based on the closing price of the Company’s common stock on the grant date, or the modification date, if any.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration